Alpha virus-based cytomegalovirus vaccines
AssigneeAlpha Vax, Inc.
InventorsJeffrey D. Chulay, Sergey Dryga, Elizabeth A. Reap, Robert A. Olmsted, John S. Morris
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising alphavirus replicon RNAs, wherein a first replicon RNA comprises nucleic acid encoding cytomegalovirus pp65 and IE1 protein or immunogenic fragments thereof, and a second replicon RNA comprises nucleic acid encoding cytomegalovirus gB protein or an immunogenic fragment thereof, and wherein each of the two replicon RNAs is contained within a separate alphavirus replicon particle.
Claims50
A population of alphavirus replicon particles wherein said particles comprise alphavirus replicon RNAs, wherein a first replicon RNA comprises nucleic acid encoding a fusion protein of cytomegalovirus pp65 and IE1 proteins or epitopes thereof, and a second replicon RNA comprises nucleic acid encoding cytomegalovirus gB protein or an epitope thereof, and wherein each of the first and second replicon RNAs is contained within a separate alphavirus replicon particle.
A population of alphavirus replicon particles wherein said particles comprise a replicon RNA which comprises a regulatory cassette that directs transcription and translation of a nucleic acid encoding a fusion protein of cytomegalovirus pp65 and IE1 proteins, or epitopes thereof.
Dependencies are inferred from the claim text.